Tamoxifen Tablets 10mg/tab 100 Tabletten by Genesis

Usage

1. Confirm your cycle has fully cleared: allow sufficient washout time based on the longest-acting ester used (e.g., wait 14–18 days after the final Testosterone Enanthate injection) before initiating Tamoxifen Citrate.
2. Obtain baseline bloodwork — total testosterone, free testosterone, LH, FSH, and estradiol — to document your suppression level and establish a recovery reference point.
3. Begin the induction phase at 40 mg/day (four × 10 mg Genesis tablets), taken orally with or without food. Consistency of timing each day supports stable plasma levels given Tamoxifen's approximately 5–7 day half-life.
4. At the start of Week 3, step down to 20 mg/day (two tablets). Continue without interruption through Week 4.
5. If mid-protocol bloodwork at Week 4 shows testosterone still below the lower reference limit, extend the maintenance phase or proceed to the optional 10 mg/day consolidation for Weeks 5–6.
6. Obtain post-PCT bloodwork four to six weeks after completing therapy to confirm full hormonal restoration. Store remaining Genesis Tamoxifen Citrate tablets in a cool, dry location away from direct light, in the original sealed packaging, to maintain declared potency to expiry.

Warnings

Frequently asked questions

What does a standard PCT protocol look like after a moderate anabolic cycle?

A standard PCT after a moderate cycle typically runs four to six weeks using a front-loaded, stepdown structure: 40 mg/day (four × 10 mg tablets) for weeks one and two, followed by 20 mg/day for weeks three and four, with an optional 10 mg/day consolidation week thereafter. This phased approach targets the higher suppression depth characteristic of multi-compound or extended single-compound cycles, giving the hypothalamic-pituitary axis adequate stimulation time to normalise gonadotropin output.

How long does testosterone recovery typically take after a moderate cycle with Tamoxifen Citrate?

Recovery timelines after moderate cycles vary by compound half-lives and individual response, but clinical observations and user-reported data consistently place meaningful LH and testosterone restoration within three to five weeks of initiating Tamoxifen Citrate at appropriate doses. Full return to baseline — often defined as endogenous testosterone reaching pre-cycle reference range values — generally requires four to six weeks of uninterrupted SERM therapy, assuming no underlying primary hypogonadism.

Why is dosing accuracy particularly important during a phased moderate-cycle PCT?

During a stepdown PCT, each dose reduction is a deliberate signal to the hypothalamic-pituitary system. If tablet potency deviates from its stated value, the physiological stimulus at each phase is miscalibrated — too low at induction risks insufficient gonadotropin response; too high at taper may overshoot and disrupt the natural re-establishment of feedback sensitivity. Genesis Tamoxifen Citrate undergoes HPLC content uniformity testing per batch, so each 10 mg tablet delivers a verified, consistent pharmacological dose across all protocol stages.

Can a 10 mg/tab format be used without splitting tablets across different protocol phases?

Yes — the 10 mg denomination is ideally suited to whole-tablet dosing at every phase of a moderate-cycle PCT. Induction at 40 mg/day uses four tablets, the maintenance phase at 20 mg/day uses two, and a consolidation step at 10 mg/day uses one — no cutting, no dose estimation, and no potency loss from tablet fracture. This makes the Genesis 100-tablet pack a practical, all-in-one supply for a complete six-week structured protocol.

How does the 10 mg concentration compare to higher-dose Tamoxifen tablets for PCT flexibility?

The 10 mg concentration is the lowest unit dose available in this product group, which makes it the most flexible option for fine-grained dose adjustments. Higher-strength tablets (20 mg) simplify fixed-dose regimens but require splitting to achieve 10 mg steps, introducing potency variability. The Genesis 10 mg tablet eliminates that trade-off: users at any phase of a stepdown protocol reach their target dose with whole tablets, preserving the manufacturing-verified potency that HPLC release testing guarantees. (2) angle_used

Manufacturer

Genesis applies its most rigorous incoming-material controls to the tamoxifen citrate API used in this oral tablet line, acknowledging that a SERM intended for post-cycle endocrine restoration must meet a higher accuracy standard than a general-purpose supplement. The release architecture for this product line assigns a dedicated HPLC quantification step — referenced against a certified tamoxifen citrate primary standard — to every finished-tablet batch, confirming that per-tablet content aligns with the declared 10 mg within validated acceptance criteria. Endotoxin burden is assessed using the LAL (Limulus Amebocyte Lysate) method, a test methodology conventionally reserved for parenteral products and applied here to the solid oral form as an additional safety layer. GMP-compliant manufacturing conditions govern each production stage from API intake through tableting, packaging, and sealed-batch release. Stability of declared potency across the product's shelf-life is confirmed under ICH Q1A(R2)-aligned controlled-stability protocols, providing an evidence-based expiry date rather than a commercially estimated one.